Discovery of Potential Phytochemicals from Carica papaya Targeting BRCA-1 in Breast Cancer Treatment

Area of Science:

• Biochemistry
• Computational Biology
• Pharmacology

Background:

• BRCA1 and BRCA2 genes are crucial for DNA integrity and preventing uncontrolled cell growth.
• Mutations in BRCA1/BRCA2 are linked to hereditary breast cancers, necessitating novel therapeutic strategies.
• Drug development for breast cancer treatment requires identifying effective therapeutic agents.

Purpose of the Study:

• To investigate the potential of phytochemicals from Carica papaya as therapeutic agents against the BRCA1 gene.
• To evaluate the in silico drug-likeness and pharmacokinetic properties of identified Carica papaya compounds.

Main Methods:

• In silico computational methods were employed to screen phytochemicals from Carica papaya.
• Pharmacokinetic, pharmacodynamic, ADMET, and drug-likeness studies were conducted.
• Density Functional Theory (DFT) and molecular docking were utilized to assess compound reactivity and target interactions.

Main Results:

• Carica papaya compounds exhibited favorable pharmacokinetic profiles, adhering to the Rule of Five with good bioavailability.
• In silico screening identified several compounds with promising ADMET and drug-likeness scores, indicating potential as BRCA1 drug candidates.
• DFT analysis confirmed favorable biological and chemical reactivity, and molecular docking revealed high affinity binding to BRCA1 targets.

Conclusions:

• Phytochemicals from Carica papaya demonstrate significant potential as novel therapeutic agents for BRCA1-related breast cancer.
• The identified compounds warrant further investigation for their efficacy and safety in preclinical and clinical studies.